Phase 2a Study of VTX3232 in Parkinson's Disease

Summary

This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.

Timeline

Start

2024-08-08

Primary completion

2025-04-04

Completion

2025-04-04

Drugs

Indications